TP53 and prostate cancer: In several non-prostate cancer types, we found that CTNNB1 expression was also significantly higher in TP53 mutated, but not TP53-null or WT breast and pancreatic cancer patient samples, but no correction was observed in bladder and colon cancer samples (Supplementary Fig. S6h).